Editorial brief continued
radiopharmaceutical company
- Under the agreement, Curium US will purchase all outstanding shares of Lantheus for $102.50 per share upon closing.
- Lantheus' shareholders are also set to receive non-transferable contingent value rights (CVRs) that could provide up to an additional $12.00 per share if certain commercial milestones for the company's product portfolio are met by 2030.
Event:
Primary source published:
Catalayer published: · Modified:
What happened
Curium to acquire Lantheus in all-cash deal worth up to $8bn The combined entity would operate in over 70 countries · Pharmaceutical Technology Salong Debbarma Tue, August 4, 2026 at 6:43 PM GMT+9 2 min read CapVest Partners-backed Curium has agreed to buy rival US-based radiopharmaceutical company Lantheus in an all-cash deal worth up to nearly $8bn. The deal will take the Nasdaq-listed Lantheus private. Under the agreement, Curium US will purchase all outstanding shares of Lantheus for $102.50 per share upon closing.
Primary evidence
Primary reporting sourced from Pharmaceutical Technology (https://finance.yahoo.com/healthcare/articles/curium-acquire-lantheus-cash-deal-094311084.html). All transaction figures, dates, and statements cross-referenced against wire feeds.
Why it matters
As a significant MERGER ACQUISITION development, this event shifts institutional capital allocations across Financials, Corporate Intelligence and directly alters operating assumptions for related benchmarks.
Transmission mechanisms
Market transmission operates through supply chain linkages, cost-of-capital adjustments, and sector re-rating across Financials, Corporate Intelligence, impacting near-term valuation multiples for related benchmarks.
Uncertainties and competing interpretations
Key execution risks include duration delays, regulatory scrutiny across Financials, Corporate Intelligence, and whether secondary price discovery sustains support for related benchmarks amid macro rotation.
What to monitor next
Key upcoming milestones include official regulatory disclosures, next quarterly SEC filings, and volume-weighted institutional accumulation in related benchmarks.
[S1] Pharmaceutical Technology Disclosure & Report
Original factual event report published via Pharmaceutical Technology (https://finance.yahoo.com/healthcare/articles/curium-acquire-lantheus-cash-deal-094311084.html). Verified factual financial record with zero synthetic quotes.
Track Real-Time Market Intelligence & Corporate Catalysts
Catalayer News transforms corporate filings, earnings disclosures, and market events into deterministic intelligence signals.